Health insurance is your safety net. It promises to protect your savings and your future in the event of an accident or illness. Today, thousands of Americans dependent on biologic drugs for the treatment of rheumatoid arthritis, lupus, psoriasis, MS and Crohn’s and are finding this promise empty.
Many commercial insurance plans have placed the costliest drugs, like biologics, in "specialty tiers." Insurers pay only a small percent of specialty tier drug costs, leaving patients to pick up the tab. Drugs that were formerly covered with $30 or $50 co-pays now cost patients hundreds or thousands of dollars each month to access.
It is simply unacceptable that people with rheumatoid arthritis, lupus, and psoriatic arthritis are subjected to unfair and discriminatory insurance policies. These medications help people live their lives to the fullest and from becoming disabled.
The Patients' Access to Treatments Act of 2012 (H.R. 4209 / PATA) restores insurance to its founding principles: a system of protection for people in their time of need. If enacted, PATA will limit commercial health insurers from charging more for biologic treatments than they do for other non-preferred brand drugs.
PATA had a strong bipartisan introduction but needs more sponsors to get the attention needed to pass.
Eric needs your help getting other Members of Congress to sponsor this legislation. Please ask your U.S. Representative to sponsor PATA and end discrimination against people with arthritis.